BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32266135)

  • 1. Multi-Institutional Analysis of Synchronous Prostate and Rectosigmoid Cancers.
    Jacobs CD; Trotter J; Palta M; Moravan MJ; Wu Y; Willett CG; Lee WR; Czito BG
    Front Oncol; 2020; 10():345. PubMed ID: 32266135
    [No Abstract]   [Full Text] [Related]  

  • 2. The curative management of synchronous rectal and prostate cancer.
    Lavan NA; Kavanagh DO; Martin J; Small C; Joyce MR; Faul CM; Kelly PJ; O'Riordain M; Gillham CM; Armstrong JG; Salib O; McNamara DA; McVey G; O'Neill BD
    Br J Radiol; 2016; 89(1057):20150292. PubMed ID: 26539631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
    Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
    Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation.
    Feldman AS; Meyer CP; Sanchez A; Krasnova A; Reznor G; Menon M; Kibel AS; Choueiri TK; Lipsitz SR; Sun M; Trinh QD
    J Urol; 2017 Nov; 198(5):1061-1068. PubMed ID: 28552709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer.
    Koo KC; Yoo H; Kim KH; Park SU; Han KS; Rha KH; Hong SJ; Yang SC; Chung BH
    J Urol; 2015 Apr; 193(4):1239-44. PubMed ID: 25444987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities.
    Nihei K; Ogino T; Onozawa M; Murayama S; Fuji H; Murakami M; Hishikawa Y
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):390-6. PubMed ID: 20832180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
    Thompson IM; Tangen CM; Paradelo J; Lucia MS; Miller G; Troyer D; Messing E; Forman J; Chin J; Swanson G; Canby-Hagino E; Crawford ED
    JAMA; 2006 Nov; 296(19):2329-35. PubMed ID: 17105795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer.
    Sverrisson I; Folkvaljon F; Chabok A; Stattin P; Smedh K; Nikberg M
    Eur J Surg Oncol; 2019 Mar; 45(3):341-346. PubMed ID: 30503046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid.
    Mak AC; Rich TA; Schultheiss TE; Kavanagh B; Ota DM; Romsdahl MM
    Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):597-603. PubMed ID: 8113102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
    Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
    Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
    Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
    Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
    Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Patel DN; Jha S; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Chapin BF; Freedland SJ
    Int J Urol; 2018 Dec; 25(12):998-1004. PubMed ID: 30253446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anastomotic leak following low anterior resection in stage IV rectal cancer is associated with poor survival.
    Smith JD; Butte JM; Weiser MR; D'Angelica MI; Paty PB; Temple LK; Guillem JG; Jarnagin WR; Nash GM
    Ann Surg Oncol; 2013 Aug; 20(8):2641-6. PubMed ID: 23385965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
    Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
    Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.